MARKET

CBIO

CBIO

Crescent Biopharma Inc
NASDAQ
15.16
+1.66
+12.30%
After Hours: 15.21 +0.05 +0.33% 16:51 03/27 EDT
OPEN
13.29
PREV CLOSE
13.50
HIGH
15.19
LOW
12.98
VOLUME
427.56K
TURNOVER
--
52 WEEK HIGH
28.77
52 WEEK LOW
8.72
MARKET CAP
417.76M
P/E (TTM)
-1.0124
1D
5D
1M
3M
1Y
5Y
1D
Crescent Biopharma grants inducement options for 35,325 shares; exercise price set at $13.50
Reuters · 37m ago
Crescent Biopharma Announces Grants of Inducement Awards
Barchart · 5h ago
Weekly Report: what happened at CBIO last week (0316-0320)?
Weekly Report · 4d ago
Crescent Biopharma Files Prospectus For Resale Of Up To ~19.7M Shares By Selling Securityholders From Private Placement And Warrants
Benzinga · 03/17 20:32
CRESCENT BIOPHARMA INC - FILES FOR PROSPECTUS OF RESALE OF UP TO 19.6 MLN ORDINARY SHARES OFFERED BY SELLING SECURITYHOLDERS - SEC FILING
Reuters · 03/17 20:25
Weekly Report: what happened at CBIO last week (0309-0313)?
Weekly Report · 03/16 09:42
Weekly Report: what happened at CBIO last week (0302-0306)?
Weekly Report · 03/09 09:44
Crescent Biopharma Grants Inducement Stock Options Under 2025 Incentive Plan
Reuters · 03/06 21:18
More
About CBIO
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

Webull offers Crescent Biopharma Inc stock information, including NASDAQ: CBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CBIO stock methods without spending real money on the virtual paper trading platform.